The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Some providers may need to reduce services, lay off staff or close their doors if Congress enacts major cuts to the ...

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

Sales of the company’s copycat to J&J’s blockbuster reached $150 million in the first quarter, adding to a surge in revenue ...